09:26 AM EST - Oncolytics Biotech : Today announced recent operational highlights and financial results for the first quarter ended March 31, 2023. Highlights include Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Guidance on the registration paths for pelareorep in HR+/HER2- metastatic breast and first-line pancreatic cancer expected in H2 2023. $29.7 million in cash, cash equivalents, and marketable securities as of March 31, 2023 provides projected cash runway for at least 12 months. Oncolytics Biotech
shares T.ONC are trading -$0.22 at $1.98.
Full Press Release: https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-first-quarter-2023-financial-results-and-operational-highlights-301816734.html
